Sulindac sulfide
SIGMA/S3131 - ≥98% (HPLC), solid
Synonym: (Z)
CAS Number: 32004-67-4
Empirical Formula (Hill Notation): C20H17FO2S
Molecular Weight: 340.41
EC Number: 250-892-2
MDL Number: MFCD00869764
Linear Formula: C20H17FO2S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow |
| form | solid |
| InChI | 1S/C20H17FO2S/c1-12-17(9- |
| InChI key | LFWHFZJPXXOYNR-MFOYZWKCSA |
| Quality Level | 200  |
| SMILES string | [H]C(c1ccc(SC)cc1)=C2/C( |
| solubility | DMSO: ≥22 mg/mL |
| Application: | Human endothelial cells, HMEC-1 were treated with Sulindac sulfide and the effect on cell survival was studies by MTT assay. |
| Biochem/physiol Actions: | Sulindac sulfide is a non-steroidal anti-inflammatory compound with a preference for COX-1; it is an inhibitor of Ras activation of Raf-1. It impairs nucleotide exchange on Ras by CDC25 and accelerates Ras hydrolysis of GTP by p120GAP. It is an active metabolite of sulindac. It is also shown to inhibit growth and induce apoptosis in human prostate cancer cells through a COX-1 and COX-2 independent mechanism. Sulindac sulfide is an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells and reduces tumor burden in adenomatous polyposis patients. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |   GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 - H317 - H334 - H361 |
| Precautionary statements | P201 - P280 - P301 + P312 + P330 - P302 + P352 - P308 + P313 |
| Hazard Codes | Xn |
| Risk Statements | 63-22-42/43 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |